UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022155
Receipt number R000025530
Scientific Title Effect of SGLT-2 inhibitors on Hepatic Steatosis and Fibrosis Estimated by using Fibroscan with Type 2 Diabetes Suffering from Non-alcoholic Fatty Liver Disease
Date of disclosure of the study information 2016/05/01
Last modified on 2018/03/12 08:51:42

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of SGLT-2 inhibitors on Hepatic Steatosis and Fibrosis Estimated by using Fibroscan with Type 2 Diabetes Suffering from Non-alcoholic Fatty Liver Disease

Acronym

STHENIC trial

Scientific Title

Effect of SGLT-2 inhibitors on Hepatic Steatosis and Fibrosis Estimated by using Fibroscan with Type 2 Diabetes Suffering from Non-alcoholic Fatty Liver Disease

Scientific Title:Acronym

STHENIC trial

Region

Japan


Condition

Condition

Type 2 Diabetes Suffering from
Non-alcoholic Fatty Liver Disease

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect of SGLT-2 inhibitors on hepatic steatosis and fibrosis estimated by fibroscan, visceral fat area measured, Body composition and endothelial function

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The change of hepatic steatosis between SGLT-2 inhibitors group(Additional treatment with SGLT-2 inhibitor) and control group (aggressive conventional treatment without SGLT-2 inhibitors) at 24 weeks after starting this trial.

Key secondary outcomes

The change of visceral fat area
The change of body composition
The change of endothelial function
The change of NAFLD fibrosis score,NAFIC score,FIB-4index and M2BPGi
The change of oxidative,apoptosis markers and inflammatory cytokines.
These changes will be evaluated at base line, 24 weeks between two groups


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Additional treatment with SGLT-2 inhibitor (SGLT-2 inhibitor group) for 24 weeks administration.

Interventions/Control_2

Aggressive conventional treatment (control).
(Excluding treatment with SGLT-2inhibitor and increase a dose of metformin,pioglitazone and GLP-1 receptor agonist)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Type 2 diabetes patients
2. Diagnosed fatty liver by sonography
3. Oral administration of metformin
4. Satisfying diagnostic criteria of NAFLD

Patients were prospectively assigned to either additional treatment with SGLT-2 inhibitors(n=30) or aggressive conventional treatment (control, n=30) for 6 months.

Key exclusion criteria

1) Type 1 diabetes
2) Severe diabetic complications such as ketoacidosis
3) Severe renal dysfunction(estimated glomerular filtration rate [eGFR] < 30 mL/min/)
4) Pregnant or nursing women and those who might be pregnant
5) Chronic heart failure,
6) Haemodialysis,
7) A history of stroke and cardiovascular events,
8) Any patient whom the investigator judged to be inappropriate for this study. Patients were given detailed explanations of the study protocol.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshimasa Aso

Organization

Dokkyo Medical University

Division name

Endocrinology and Metabolism

Zip code


Address

880, Kitakobayashi, Mibu, Shimotsugagun, Tochigi

TEL

0282-87-2150

Email

yaso@dokkyomed.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kunihiro Suzuki

Organization

Dokkyo Medical University

Division name

Endocrinology and Metabolism

Zip code


Address

880, Kitakobayashi, Mibu, Shimotsugagun, Tochigi

TEL

0282-87-2150

Homepage URL


Email

kuni-s@dokkyomed.ac.jp


Sponsor or person

Institute

Dokkyo Medical University

Institute

Department

Personal name



Funding Source

Organization

Dokkyo Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 05 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 04 Month 12 Day

Date of IRB


Anticipated trial start date

2016 Year 05 Month 01 Day

Last follow-up date

2018 Year 09 Month 30 Day

Date of closure to data entry

2019 Year 03 Month 31 Day

Date trial data considered complete

2019 Year 09 Month 30 Day

Date analysis concluded

2019 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2016 Year 04 Month 30 Day

Last modified on

2018 Year 03 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025530


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name